Cellular and molecular biology of esophageal cancer

Esophageal Cancer: Prevention, Diagnosis and Therapy

Volumn , Issue , 2015, Pages 25-40

  Lam, Alfred King Yin ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944227068     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-20068-2_2     Document Type: Chapter

References (85)

1. Lam KY, Ma L. Pathology of esophageal cancers: local experience and current insights. Chin Med J. 1997;110:459-64.
2. Lam AKY. Critical review: molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol. 2000;33:71-90.
3. Lam KY, Law S, Tung PH, Wong J. Esophageal basaloid squamous cell carcinoma: an unique clinicopathological entity with telomerase activity as a prognostic indicator. J Pathol. 2001;195: 435-42.
4. Lam KY, Law SYK, Loke SL, Fok M, Ma LT. Double sarcomatoid carcinomas of the esophagus. Path Res Pract. 1996;192:604-9.
5. Lam KY, Dickens P, Loke SL, Fok M, Ma L, Wong J. Squamous cell carcinoma of the esophagus with mucin-secreting component (mucoepidermoid carcinoma and adenosquamous cell carcinoma): a clinicopathologic study and a review of literature. Eur J Surg Oncol. 1994;20: 25-31.
6. Law SYK, Fok M, Lam KY, Loke SL, Ma LT, Wong J. Small cell carcinoma of the esophagus. Cancer. 1994;73:2894-9.
7. Chow V, Law S, Lam KY, Luk JM, Wong J. Telomerase activity in small cell esophageal carcinoma. Dis Esophagus. 2001;14:139-42.
8. Lam KY, Law S, Tung PH, Wong J. Esophageal small cell carcinoma: clinicopathologic parameters, p53 overexpression, proliferative marker, and their impact on pathogenesis. Arch Pathol Lab Med. 2000;124:228-33.
9. Garbuglia AR. Human papillomavirus in head and neck cancer. Cancers (Basel). 2014;6: 1705-26.
10. Salazar CR, Anayannis N, Smith RV, Wang Y, Haigentz Jr M, Garg M, Schiff BA, Kawachi N, Elman J, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF. Combined p16 and human papillomavirus testing predicts head and neck cancer survival. Int J Cancer. 2014;135:2404-12.
11. Westra WH. Detection of human papillomavirus (HPV) in clinical samples: evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas. Oral Oncol. 2014;50:771-9.
12. He D, Zhang DK, Lam KY, Ma L, Ngan HYS, Liu SS, Tsao SW. Prevalence of HPV infection in esophageal squamous cell carcinoma in Chinese patients and its relationship to the p53 gene mutation. Int J Cancer. 1997;72:959-64.
13. Lam KY, He D, Ma L, Zhang D, Ngan HYS, Wan TSK, Tsao SW. Presence of human papillomavirus in esophageal squamous cell carcinomas of Hong Kong Chinese and its relationship with p53 gene mutation. Hum Pathol. 1997;28:657-63.
14. Li X, Gao C, Yang Y, Zhou F, Li M, Jin Q, Gao L. Systematic review with meta-analysis: the association between human papillomavirus infection and oesophageal cancer. Aliment Pharmacol Ther. 2014;39:270-81.
15. Lofdahl HE, Du J, Nasman A, Andersson E, Rubio CA, Lu Y, Ramqvist T, Dalianis T, Lagergren J, Dahlstrand H. Prevalence of human papillomavirus (HPV) in oesophageal squamous cell carcinoma in relation to anatomical site of the tumour. PLoS One. 2012;7, e46538.
16. Vaiphei K, Kochhar R, Bhardawaj S, Dutta U, Singh K. High prevalence of human papillomavirus in esophageal squamous cell carcinoma: a study in paired samples. Dis Esophagus. 2013;26:282-7.
17. Al-Haddad S, El-Zimaity H, Hafezi-Bakhtiari S, Rajendra S, Streutker CJ, Vajpeyi R, Wang B. Infection and esophageal cancer. Ann N Y Acad Sci. 2014;1325:187-96.
18. Lam KY, Srivastava G, Leung ML, Ma L. Absence of Epstein-Barr virus in esophageal squamous cell carcinoma: a study of 74 cases using in-situ hybridization. J Clin Pathol Mol Pathol. 1995;48:M188-90.
19. Wang ZK, Yang YS. Upper gastrointestinal microbiota and digestive diseases. World J Gastroenterol. 2013;19:1541-50.
20. Gibson MK, Dhaliwal AS, Clemons NJ, Phillips WA, Dvorak K, Tong D, Law S, Pirchi ED, Rasanen J, Krasna MJ, Parikh K, Krishnadath KK, Chen Y, Griffiths L, Colleypriest BJ
21. Farrant JM, Tosh D, Das KM, Bajpai M. Barrett’s esophagus: cancer and molecular biology. Ann N Y Acad Sci. 2013;1300:296-314.
22. Lam KY, Tsao SW, Zhang D, Law S, He D, Ma L, Wong J. Prevalence and predictive value of p53 mutation in patients with esophageal squamous cell carcinomas: a prospective clinico- pathological study and survival analysis of 70 patients. Int J Cancer. 1997;74:212-9.
23. Appelman HD, Matejcic M, Parker MI, Riddell RH, Salemme M, Swanson PE, Villanacci V. Progression of esophageal dysplasia to cancer. Ann N Y Acad Sci. 2014;1325:96-107.
24. Pack SD, Karkera JD, Zhuang Z, Pak ED, Balan KV, Hwu P, Park WS, Pham T, Ault DO, Glaser M, Liotta L, Detera-Wadleigh SD, Wadleigh RG. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Genes Chromosomes Cancer. 1999;25:160-8.
25. Walch AK, Zitzelsberger HF, Bruch J, Keller G, Angermeier D, Aubele MM, Mueller J, Stein H, Braselmann H, Siewert JR, Hofler H, Werner M. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol. 2000;156: 555-66.
26. Kwong D, Lam A, Guan X, Law S, Tai A, Wong J, Sham J. Chromosomal aberrations in esophageal squamous cell carcinoma among Chinese: gain of 12p predicts poor prognosis after surgery. Hum Pathol. 2004;35:309-16.
27. Qin YR, Wang LD, Fan ZM, Kwong D, Guan XY. Comparative genomic hybridization analysis of genetic aberrations associated with development of esophageal squamous cell carcinoma in Henan, China. World J Gastroenterol. 2008;14:1828-35.
28. Tang JCO, Lam KY, Law S, Wong J, Srivastava G. Detection of genetic alterations in esophageal squamous cell carcinomas and adjacent normal epithelia by comparative DNA fingerprinting using inter-simple sequence repeat PCR. Clin Cancer Res. 2001;7:1539-45.
29. Hu YC, Lam KY, Law S, Wong J, Srivastava G. Identification of differentially expressed in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1 and CDC25B genes in ESCC. Clin Cancer Res. 2001;7:2213-21.
30. Fatima S, Chui CH, Tang WK, Hui KS, Au HW, Li WY, Wong MM, Cheung F, Tsao SW, Lam KY, Beh PS, Wong J, Law S, Srivastava G, Ho KP, Chan AS, Tang JC. Transforming capacity of two novel genes JS-1 and JS-2 located in chromosome 5p and their overexpression in human esophageal squamous cell carcinoma. Int J Mol Med. 2006;17:159-70.
31. Tang WK, Chui CH, Fatima S, Kok SH, Pak KC, Ou TM, Hui KS, Wong MM, Wong J, Law S, Tsao SW, Lam KY, Beh PS, Srivastava G, Chan AS, Ho KP, Tang JC. Oncogenic properties of a novel gene JK-1 located in chromosome 5p and its overexpression in human esophageal squamous cell carcinoma. Int J Mol Med. 2007;19:915-23.
32. Goh XY, Rees JR, Paterson AL, Chin SF, Marioni JC, Save V, O’Donovan M, Eijk PP, Alderson D, Ylstra B, Caldas C, Fitzgerald RC. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut. 2011;60:1317-26.
33. Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett. 2013;340:284-95.
34. Zhang J, Baran J, Cros A, Guberman JM, Haider S, Hsu J, Liang Y, Rivkin E, Wang J, Whitty B, Wong-Erasmus M, Yao L, Kasprzyk A. International cancer genome consortium data portal-a one-stop shop for cancer genomics data. Database (Oxford). 2011;2011: bar026.
35. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, Ma X, Liu L, Zhao Z, Huang X, Fan J, Dong L, Chen G, Ma L, Yang J, Chen L, He M, Li M, Zhuang X, Huang K, Qiu K, Yin G, Guo G, Feng Q, Chen P, Wu Z, Wu J, Ma L, Zhao J, Luo L, Fu M, Xu B, Chen B, Li Y, Tong T, Wang M, Liu Z, Lin D, Zhang X, Yang H, Wang J, Zhan Q. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91-5.
36. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, Sivachenko A, Saksena G, Voet D, Ramos AH, Auclair D, Thompson K, Sougnez C, Onofrio RC, Guiducci C, Beroukhim R, Zhou Z, Lin L, Lin J, Reddy R, Chang A, Landrenau R, Pennathur A, Ogino S, Luketich JD, Golub TR, Gabriel SB, Lander ES, Beer DG, Godfrey TE, Getz G, Bass AJ. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45:478-86.
37. Nones K, Waddell N, Wayte N, Patch AM, Bailey P, Newell F, Holmes O, Fink JL, Quinn MC, Tang YH, Lampe G, Quek K, Loffler KA, Manning S, Idrisoglu S, Miller D, Xu Q, Waddell N, Wilson PJ, Bruxner TJ, Christ AN, Harliwong I, Nourse C, Nourbakhsh E, Anderson M, Kazakoff S, Leonard C, Wood S, Simpson PT, Reid LE, Krause L, Hussey DJ, Watson DI, Lord RV, Nancarrow D, Phillips WA, Gotley D, Smithers BM, Whiteman DC, Hayward NK, Campbell PJ, Pearson JV, Grimmond SM, Barbour AP. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun. 2014;5:5224.
38. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, Sato Y, Okuno Y, Varela AM, Ding LW, Garg M, Liu LZ, Yang H, Yin D, Shi ZZ, Jiang YY, Gu WY, Gong T, Zhang Y, Xu X, Kalid O, Shacham S, Ogawa S, Wang MR, Koeffler HP. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet. 2014;46:467-73.
39. Gopalan V, Pillai S, Ebrahimi F, Salajegheh A, Lam TC, Le TK, Langsford N, Ho YH, Smith RA, Lam AK. Regulation of microRNA-1288 in colorectal cancer: altered expression and its clinicopathological significance. Mol Carcinog. 2014;53:E36-44.
40. Ebrahimi F, Gopalan V, Smith RA, Lam AK. miR-126 in human cancers: clinical roles and current perspectives. Exp Mol Pathol. 2014;96:98-107.
41. Maroof H, Salajegheh A, Smith RA, Lam AK. Role of microRNA-34 family in cancer with particular reference to cancer angiogenesis. Exp Mol Pathol. 2014;97:298-304.
42. Vosgha H, Salajegheh A, Smith RA, Lam AK. The Important Roles of miR-205 in normal physiology, cancers and as a potential therapeutic target. Curr Cancer Drug Targets. 2014; 14:621-37.
43. Yu H, Duan B, Jiang L, Lin M, Sheng H, Huang J, Gao H. Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy. Am J Transl Res. 2013;6:71-7.
44. Wu C, Li M, Hu C, Duan H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep. 2014;41:1257-66.
45. Matsuzaki J, Suzuki H. MicroRNAs in Barrett’s esophagus: future prospects. Front Genet. 2014;5:69.
46. Sakai NS, Samia-Aly E, Barbera M, Fitzgerald RC. A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol. 2013;23:512-21.
47. Gu J, Wang Y, Wu X. MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des. 2013;19:1292-300.
48. Amin M, Lam AK. Current perspectives of mi-RNA in oesophageal adenocarcinoma: Roles in predicting carcinogenesis, progression and values in clinical management. Exp Mol Pathol. 2015;98:411-8.
49. Islam F, Qiao B, Smith RA, Gopalan V, Lam AK. Cancer stem cell: Fundamental experimental pathological concepts and updates. Exp Mol Pathol. 2015;98:184-91.
50. Qiao B, Gopalan V, Chen Z, Smith RA, Tao Q, Lam AKY. Epithelial-mesenchymal transition and mesenchymal-epithelial transition are essential for the acquisition of stem cell properties in hTERT-immortalised oral epithelial cells. Bio Cell. 2012;104:476-89.
51. Islam F, Gopalan V, Smith RA, Lam AK. Translational potential of cancer stem cells: A review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment. Exp Cell Res. 2015;335:135-47.
52. Wang Z, Da Silva TG, Jin K, Han X, Ranganathan P, Zhu X, Sanchez-Mejias A, Bai F, Li B, Fei DL, Weaver K, Carpio RV, Moscowitz AE, Koshenkov VP, Sanchez L, Sparling L, Pei XH, Franceschi D, Ribeiro A, Robbins DJ, Livingstone AS, Capobianco AJ. Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Res. 2014;74:6364-74.
53. di Pietro M, Alzoubaidi D, Fitzgerald RC. Barrett’s esophagus and cancer risk: how research advances can impact clinical practice. Gut Liver. 2014;8:356-70.
54. Ong CAJ, Lao-Sirieix P, Fitzgerald RC. Biomarkers in Barrett’s esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol. 2010;16: 5669-81.
55. Chen M, Huang J, Zhu Z, Zhang J, Li K. Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer. 2013;13:539.
56. Shang L, Liu HJ, Hao JJ, Jiang YY, Shi F, Zhang Y, Cai Y, Xu X, Jia XM, Zhan QM, Wang MR. A panel of overexpressed proteins for prognosis in esophageal squamous cell carcinoma. PLoS One. 2014;9, e111045.
57. Chung Y, Lam AK, Luk JM, Law S, Chan KW, Lee PY, Wong J. Altered E-cadherin expression and p120 catenin localization in esophageal squamous cell carcinoma. Ann Surg Oncol. 2007;14:3260-7.
58. Chan D, Tsoi MY, Liu CD, Chan SH, Law SY, Chan KW, Chan YP, Gopalan V, Lam AK, Tang JC. Oncogene GAEC1 regulates CAPN10 expression which predicts survival in esophageal squamous cell carcinoma. World J Gastroenterol. 2013;19:2772-80.
59. Lam KY, Law S, Lo T, Tung HM, Wong J. The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients. Am J Gastroenterol. 1999;94:2060-8.
60. Lam KY, Law SYK, So MKP, Fok M, Ma LT, Wong J. Prognostic implication of proliferative markers MIB-1 and PC 10 in esophageal squamous cell carcinoma. Cancer. 1996;77:7-13.
61. Tong DK, Law S, Kwong DL, Chan KW, Lam AK, Wong KH. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol. 2010;17: 2184-92.
62. Lam KY, Law S, Ma LT, Ong SK, Wong J. Pre-operative chemotherapy for squamous cell carcinoma of the esophagus: do histological assessment and p53 overexpression predict chemo-responsiveness? Eur J Cancer. 1997;33:1221-5.
63. Okumura H, Uchikado Y, Setoyama T, Matsumoto M, Owaki T, Ishigami S, Natsugoe
64. S. Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy. Surg Today. 2014;44:421-8.
65. Zhang SS, Huang QY, Yang H, Xie X, Luo KJ, Wen J, Cai XL, Yang F, Hu Y, Fu JH. Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a metaanalysis. Ann Surg Oncol. 2013;20:2419-27.
66. Bain GH, Petty RD. Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist. 2010;15: 270-84.
67. Imdahl A, Jenkner J, Ihling C, Ruckauer K, Farthmann EH. Is MIB-1 proliferation index a predictor for response to neoadjuvant therapy in patients with esophageal cancer? Am J Surg. 2000;179:514-20.
68. Ung L, Lam AK, Morris DL, Chua TC. Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review. Clin Transl Oncol. 2014;16:425-35.
69. Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013;45:346-56.
70. Rahman MA, Salajegheh A, Smith RA, Lam AK. BRAF inhibitors: from the laboratory to clinical trials. Crit Rev Oncol Hematol. 2014;90:220-32.
71. Rahman MA, Salajegheh A, Smith RA, Lam AK. BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects. Curr Cancer Drug Targets. 2014;14:128-43.
72. O’Sullivan CC, Connolly RM. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer. Oncology (Williston Park). 2014;28:186-94.
73. Wiedmann MW, Mossner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res. 2013;5:133-46.
74. Kordes S, Cats A, Meijer SL, van Laarhoven HW. Targeted therapy for advanced esophagogastric adenocarcinoma. Crit Rev Oncol Hematol. 2014;90:68-76.
75. Xu WW, Li B, Lam AK, Tsao SW, Law SY, Chan KW, Yuan QJ, Cheung AL. Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget. 2015;6:1790-805.
76. Nakajima M, Kato H. Treatment options for esophageal squamous cell carcinoma. Expert Opin Pharmacother. 2013;14:1345-54.
77. Boland PM, Burtness B. Esophageal carcinoma: are modern targeted therapies shaking the rock? Curr Opin Oncol. 2013;25:417-24.
78. Tang JCO, Wan TSK, Wong N, Pang E, Lam KY, Law SYK, Chow LMC, Ma ESK, Chan LC, Wong J, Srivastava G. Establishment and characterization of a new xenograft-derived human esophageal squamous cell line SLMT-1 of Chinese origin. Cancer Genet Cytogenet. 2001;124: 36-41.
79. Hu YC, Lam KY, Wan TSK, Fang WG, Ma ESK, Chan LC, Srivastava G. Establishment and characterization of HKESC-1, a new cancer cell line from human esophageal squamous cell carcinoma. Cancer Genet Cytogenet. 2000;118:112-20.
80. Hu YC, Lam KY, Law SYK, Wan TSK, Ma ESK, Kwong YL, Chan LC, Wong J, Srivastava G. Establishment, characterization, karyotyping, and comparative genomic hybridization analysis of HKESC-2 and HKESC-3: two newly established human esophageal squamous cell lines. Cancer Genet Cytogenet. 2002;135:120-7.
81. Boonstra JJ, Tilanus HW, Dinjens WN. Translational research on esophageal adenocarcinoma: from cell line to clinic. Dis Esophagus. 2013;28:90-6. doi:10.1111/dote.12095.
82. Gros SJ. Orthotopic models of esophageal carcinoma and their use in drug discovery. Curr Protoc Pharmacol. 2011; Chapter 14:Unit14.20. doi:10.1002/0471141755.ph1420s54.
83. Furihata T, Sakai T, Kawamata H, Omotehara F, Shinagawa Y, Imura J, Ueda Y, Kubota K, Fujimori T. A new in vivo model for studying invasion and metastasis of esophageal squamous cell carcinoma. Int J Oncol. 2001;19:903-7.
84. Hori T, Yamashita Y, Ohira M, Matsumura Y, Muguruma K, Hirakawa K. A novel orthotopic implantation model of human esophageal carcinoma in nude rats: CD44H mediates cancer cell invasion in vitro and in vivo. Int J Cancer. 2001;92:489-96.
85. Ip JC, Ko JM, Yu VZ, Chan KW, Lam AK, Law S, Tong DK, Lung ML. A versatile Orthotopic nude mouse model for study of esophageal squamous cell carcinoma. Biomed Res Int. 2015;2015:910715.